Ensuring Successful Biomarker Studies in Bladder Preservation Clinical Trials for Non-muscle Invasive Bladder Cancer

Affiliations

• ¹ Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA.
• ² Department of Radiation Oncology, Springfield Clinic, Springfield, IL, USA.
• ³ Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA.
• ⁴ Patient Advocate, Baltimore, MD, USA.
• ⁵ Department of Pathology and Laboratory Medicine, Pennsylvania State University, Hershey, PA, USA.
• ⁶ Department of Urology, Pennsylvania State University, Hershey, PA, USA.
• ⁷ Department of Urology, Louisiana State University Health Science Center, New Orleans, New Orleans, LA, USA.
• ⁸ Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
• ⁹ Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, MD, USA.
• ¹⁰ Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
• ¹¹ US Medical Affairs and Oncology Biomarker Development, Genentech Inc., South San Francisco, CA, USA.
• ¹² Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
• ¹³ Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
• ¹⁴ Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA.
• ¹⁵ Convergent Genomics, San Francisco, CA, USA.
• ¹⁶ Department of Urology, Stanford University, Stanford, CA, USA.
• ¹⁷ Department of Urology, Feinberg School of Medicine, Chicago, IL, USA.
• ¹⁸ Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Chicago, IL, USA.
• ¹⁹ Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA, USA.
• ²⁰ Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
• ²¹ Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
• ²² Human Oncology and Pathogenesis Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
• ²³ Department of Urology, Ohio State University Comprehensive Cancer Center, Pelotonia Institute for Immuno-Oncology, Columbus, OH, USA.
• ²⁴ Coordinating Center for Clinical Trials, National Cancer Institute, NIH, Bethesda, MD, USA.
• ²⁵ Emmes Company, Rockville, MD, USA.
• ²⁶ University of North Carolina at Chapel Hill, Departments of Pathology and Laboratory Medicine and Urology, Chapel Hill, NC, USA.
• ²⁷ Vancouver Prostate Centre, Department of Urologic Sciences,University of British Columbia, Vancouver, BC, Canada.
• ²⁸ Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.
• ²⁹ Genitourinary Malignancies Branch, National Cancer Institute, Center for Cancer Research, Bethesda, MD, USA.
• ³⁰ University of British Columbia, Vancouver, BC, Canada.